Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1A | Q16819 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 6/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334445 | 0.82 | MEN1 (0.50) | OXTRAVPR1AMEN1KMT2ALMNA | |
| SCHEMBL334420 | 0.81 | PTGES (0.51) | PTGESMEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL2773062 | 0.78 | MEP1B (0.52) | MEP1AMEP1BPTGESSLC6A2SLC6A4 | |
| SCHEMBL334949 | 0.77 | ALDH1A1 (0.52) | MEN1KMT2ALMNANPC1 | |
| SCHEMBL2774324 | 0.76 | MEP1A (0.48) | MEP1AMEP1BPTGESSLC6A2SLC6A4 | |
| SCHEMBL6566687 | 0.75 | SLC6A2 (0.55) | MEP1AMEP1BPTGESSLC6A2SLC6A4 | |
| SCHEMBL6566756 | 0.75 | MEP1A (0.50) | MEP1AMEP1BPTGESMEN1KMT2A | |
| SCHEMBL16644940 | 0.74 | OXTR (0.40) | OXTRAVPR1AMEN1KMT2ACHRM2 | |
| SCHEMBL335041 | 0.73 | KMT2A (0.50) | MEN1KMT2ALMNA | |
| SCHEMBL11160181 | 0.73 | OXTR (0.53) | OXTRAVPR1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | MEP1A 17/4885MEP1B 39/4885PTGES 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.